Saccharin is a high-intensity sweetener that has been used since the late nineteenth century and remains useful because a tiny quantity produces substantial sweetness. FDA places its sweetness at roughly 200–700 times that of sucrose. In Europe, saccharin and its sodium, potassium, and calcium salts are grouped as E 954.
Its long history also explains its unusual reputation. For decades, saccharin products carried warnings related to bladder cancer findings in laboratory rats. Scientific understanding of those findings has changed substantially.
Why is a century-old sweetener still used?
Saccharin is inexpensive, potent, and stable during storage. It works in tabletop sweeteners, beverages, selected processed foods, and cooking applications under permitted conditions.
The salt forms—especially sodium saccharin—are more water-soluble than saccharin itself, making them easier to use in drinks and tablets.
Because the amount needed is so small, its energy contribution is essentially negligible. It provides sweetness but not the bulk or structural properties of sugar.
Its biggest sensory limitation is aftertaste
At sufficient concentrations, many people perceive a bitter or metallic note. Sensitivity varies among individuals and changes with the food or beverage matrix.
This is one reason saccharin can be blended with other sweeteners. A 2024 sensory and receptor study found that selected combinations could increase perceived sweetness and reduce bitterness associated with saccharin or acesulfame K.
Blending is a flavor-design strategy; it does not automatically improve the nutritional quality of the finished product.
What happened to the bladder-cancer warning?
In the 1970s, high-dose rat studies linked saccharin with bladder tumors. That evidence led the United States to require warning labels on saccharin-containing products for many years.
Later research showed that the tumor mechanism depended on biological conditions specific to male rats and was not considered relevant to humans. In 2000, the U.S. National Toxicology Program removed saccharin from its list of potential carcinogens, and the federal warning requirement ended.
EFSA’s 2024 re-evaluation reached the same key interpretation: the male-rat bladder tumors used for the previous safety limit are not relevant to human cancer risk.
EFSA increased the ADI in 2024
EFSA established a new Acceptable Daily Intake of 9 mg/kg body weight per day for saccharin and its salts, replacing older lower values.
For a 154-lb (70-kg) adult, that corresponds to 630 mg per day as the toxicological reference. EFSA’s highest estimates of chronic consumer exposure remained below the new ADI across population groups.
An ADI is not a recommended intake. It is an estimate of the amount that can be consumed every day over a lifetime without appreciable health risk.
Zero-calorie sweetness does not make the entire food calorie-free
Saccharin is used in amounts so small that its own energy is irrelevant, but the food may still contain fat, starch, protein, or other carbohydrates.
Tabletop products may also contain bulking ingredients. A sugar-free cookie or dessert can therefore remain calorie-dense even though saccharin replaces some sweetness.
Nutrition Facts and the full ingredient list still matter.
WHO’s NSS guideline does not redefine saccharin toxicology
WHO includes saccharin among non-sugar sweeteners and conditionally recommends against relying on NSS for long-term weight control or prevention of chronic disease.
The guideline explicitly says it is not a toxicological safety reassessment and does not replace ADIs set by food-safety authorities. A sweetener can be within a safety limit without being proven as a long-term weight-management tool.
Why newer sweeteners have not eliminated saccharin
Food formulation balances cost, potency, solubility, stability, availability, and flavor. Saccharin still performs well in selected applications, particularly when its aftertaste can be managed through blending.
It also has more than a century of manufacturing experience and extensive regulatory characterization. Newer does not automatically mean more useful for every food.
The practical rule: saccharin remains in use because it is potent, stable, and inexpensive. The historical rat-cancer warning does not reflect the current human risk assessment; EFSA reviewed the evidence and increased the ADI in 2024.
Frequently asked questions
Does saccharin cause cancer?
The old concern came from bladder tumors in male rats. The mechanism is considered rat-specific and not relevant to humans, and EFSA re-evaluated the evidence in 2024.
How much sweeter is saccharin than sugar?
FDA describes saccharin as roughly 200–700 times sweeter than sucrose.
What is the current saccharin ADI?
EFSA established an ADI of 9 mg/kg body weight per day for saccharin and its salts in 2024.
Sources
- EFSA — Re-evaluation of saccharin and its salts E 954 — Reevaluación de 2024 que estableció una IDA de 9 mg/kg/día y revisó la relevancia humana de los tumores de vejiga observados en ratas.
- EFSA — Saccharin: safety threshold increased — Resumen de la nueva IDA, exposición europea y cambio de interpretación del mecanismo tumoral en ratas macho.
- FDA — Aspartame and Other Sweeteners in Food — Describe dulzor de 200–700 veces la sacarosa, historia regulatoria estadounidense y retirada de la preocupación carcinogénica basada en ratas.
- PubMed — Sweet-bitter taste interactions in binary mixtures of sweeteners — Estudio de 2024 sobre mezclas con sacarina y reducción de amargor/percepción sensorial.
- WHO — Use of non-sugar sweeteners guideline — Guía condicional de salud pública sobre NSS, diferenciada de evaluaciones toxicológicas individuales.